Efficacy of olanzapine in the adjuvant treatment of post-stroke vertigo: a preliminary observation

Sheng-yun LI,Xiu-hai GUO,Min WAN,Jian WU,Jian-ping JIA

DOI: https://doi.org/10.3969/j.issn.1672-5921.2010.11.002

2010-01-01

Abstract:Objective: To investigate the therapeutic effect of olanzapine on patients with post-stroke vertigo. Methods: A total of 20 consecutive patients with ischemic stroke accompanied with severe vertigo were admitted to the stroke unit of Xuanwu Hospital, Capital Medical University from December 2009 to April 2010. They were randomly divided into a combined treatment group (n = 12) and a single treatment group (n = 8). There was no significant difference of baseline conditions of patients between the two groups before treatment. The patients in the combined treatment group took betahistine 6 mg three times a day and olanzapine 2.5 mg once every evening. The patients in the single treatment group took betahistine 6 mg three times a day. Both groups were observed for 10 days. The European Evaluation of Vertigo (EEV) scale was used as the efficacy evaluation index for patients with vertigo. Meantime, the changes of body weight, blood glucose, blood lipid, and liver function of the patients were documented. Results: Circled digit oneThe decreased relative numbers of the EEV scores at day 5 and 10 in the combined treatment group were 0.41 ±0.25 and 0.63 ±0.31 compared to those at day 1 in the single treatment group were 0.17 ±0.16 and 0.28 ±0.23. The differences were significant between the two groups (P = 0.027, P = 0.016). Circled digit twoThe differences of the EEV scores of all indexes at day 10 after the treatment between the two groups were observed. Compared to the combined treatment group, the sub-items of the activity tolerance and imbalance in the single treatment group had better recovery (P = 0.069, P = 0.031). Circled digit threeThere were no significant differences in the body mass index, blood glucose, blood lipid and liver function before and after treatment in the combined treatment group (P > 0.05). One patient was withdrawn from the observation and treatment early in the combined treatment group during the observation and treatment periods because of the increased blood glucose after starting the treatment. The increased blood glucose of the patient might be related to the adverse reactions of olanzapine. Conclusion: Olanzapine has significant efficacy for the treatment of vertigo after stroke in a small sample of patients, especially in the recovery of active ability of patients. However, its adverse reactions should pay close attention to. Its therapeutic effect needs a large sample study to confirm.